Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 397307, 11 pages
http://dx.doi.org/10.1155/2014/397307
Research Article

Taurine Alleviates the Progression of Diabetic Nephropathy in Type 2 Diabetic Rat Model

1Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-740, Republic of Korea
2Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan-Dong, Wonju, Gangwon-Do 220-701, Republic of Korea
3Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 330-721, Republic of Korea
4Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, Republic of Korea

Received 17 October 2013; Revised 27 December 2013; Accepted 7 January 2014; Published 23 February 2014

Academic Editor: Sandeep Singh

Copyright © 2014 Jang Hyun Koh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Giugliano, A. Ceriello, and G. Paolisso, “Oxidative stress and diabetic vascular complications,” Diabetes Care, vol. 19, no. 3, pp. 257–267, 1996. View at Google Scholar · View at Scopus
  2. A. R. Andersen, J. Sandahl Christiansen, and J. K. Andersen, “Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study,” Diabetologia, vol. 25, no. 6, pp. 496–501, 1983. View at Google Scholar · View at Scopus
  3. A. Flyvbjerg, “Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease,” Diabetologia, vol. 43, no. 10, pp. 1205–1223, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. D. R. Cha, N. H. Kim, J. W. Yoon et al., “Role of vascular endothelial growth factor in diabetic nephropathy,” Kidney International, vol. 58, supplement 77, pp. S104–S112, 2000. View at Google Scholar · View at Scopus
  5. K. J. Kim, B. Li, J. Winer et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature, vol. 362, no. 6423, pp. 841–844, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Gilbert, D. J. Kelly, A. J. Cox et al., “Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes,” Diabetologia, vol. 43, no. 11, pp. 1360–1367, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. M. E. Cooper, D. Vranes, S. Youssef et al., “Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes,” Diabetes, vol. 48, no. 11, pp. 2229–2239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. D. R. Cha, Y. S. Kang, S. Y. Han et al., “Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats,” Journal of Endocrinology, vol. 183, no. 1, pp. 183–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Y. Lee, M. S. Shim, M. J. Kim, S. Y. Hong, Y. G. Shin, and C. H. Chung, “Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes,” Experimental and Molecular Medicine, vol. 36, no. 1, pp. 65–70, 2004. View at Google Scholar · View at Scopus
  10. K. V. Lemley, K. Blouch, I. Abdullah et al., “Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus,” Journal of the American Society of Nephrology, vol. 11, no. 11, pp. 2095–2105, 2000. View at Google Scholar · View at Scopus
  11. K. Tryggvason and J. Wartiovaara, “Molecular basis of glomerular permselectivity,” Current Opinion in Nephrology and Hypertension, vol. 10, no. 4, pp. 543–549, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Ruotsalainen, P. Ljungberg, J. Wartiovaara et al., “Nephrin is specifically located at the slit diaphragm of glomerular podocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 14, pp. 7962–7967, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Doublier, G. Salvidio, E. Lupia et al., “Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II,” Diabetes, vol. 52, no. 4, pp. 1023–1030, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Erdem, N. Ü. Gündoǧan, A. Usubütün et al., “The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats,” Nephrology Dialysis Transplantation, vol. 15, no. 8, pp. 1175–1182, 2000. View at Google Scholar · View at Scopus
  15. F. Franconi, F. Bennardini, A. Mattana et al., “Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation,” American Journal of Clinical Nutrition, vol. 61, no. 5, pp. 1115–1119, 1995. View at Google Scholar · View at Scopus
  16. H. Trachtman, S. Futterweit, J. Maesaka et al., “Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats,” American Journal of Physiology, vol. 269, no. 3, pp. F429–F438, 1995. View at Google Scholar · View at Scopus
  17. L. Wang, L. Zhang, Y. Yu, Y. Wang, and N. Niu, “The protective effects of taurine against early renal injury in STZ-induced diabetic rats, correlated with inhibition of renal LOX-1-mediated ICAM-1 expression,” Renal Failure, vol. 30, no. 8, pp. 763–771, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Winiarska, K. Szymanski, P. Gorniak, M. Dudziak, and J. Bryla, “Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits,” Biochimie, vol. 91, no. 2, pp. 261–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Das and P. C. Sil, “Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats,” Amino Acids, vol. 43, no. 4, pp. 1509–1523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Higo, S. Miyata, Y. J. Qing, R. Kitazawa, S. Kitazawa, and M. Kasuga, “Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats,” Kobe Journal of Medical Sciences, vol. 54, no. 1, pp. 35–45, 2008. View at Google Scholar · View at Scopus
  21. S. Lin, J. Yang, G. Wu et al., “Preventive effect of taurine on experimental type II diabetic nephropathy,” Journal of Biomedical Science, vol. 17, supplement 1, p. S46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Google Scholar · View at Scopus
  23. P. H. Lane, M. W. Steffes, and S. M. Mauer, “Estimation of glomerular volume: a comparison of four methods,” Kidney International, vol. 41, no. 4, pp. 1085–1089, 1992. View at Google Scholar · View at Scopus
  24. R. J. Huxtable, “Physiological actions of taurine,” Physiological Reviews, vol. 72, no. 1, pp. 101–164, 1992. View at Google Scholar · View at Scopus
  25. C. E. Wright, H. H. Tallan, Y. Y. Lin, and G. E. Gaull, “Taurine: biological update,” Annual Review of Biochemistry, vol. 55, pp. 427–453, 1986. View at Google Scholar · View at Scopus
  26. H. Trachtman, R. Del Pizzo, S. Futterweit et al., “Taurine attenuates renal disease in chronic puromycin aminonucleoside nephropathy,” American Journal of Physiology, vol. 262, no. 1, pp. F117–F123, 1992. View at Google Scholar · View at Scopus
  27. J. S. Huang, L. Y. Chuang, J. Y. Guh, Y. Yang, and M. Hsu, “Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells,” Toxicology and Applied Pharmacology, vol. 233, no. 2, pp. 220–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Suzuki, T. Miyata, N. Saotome et al., “Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions,” Journal of the American Society of Nephrology, vol. 10, no. 4, pp. 822–832, 1999. View at Google Scholar · View at Scopus
  29. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Ha and K. H. Kim, “Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C,” Diabetes Research and Clinical Practice, vol. 45, no. 2-3, pp. 147–151, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993.
  32. R. Turner, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. W. J. Lamoreaux, C. Cuttitta, A. Santora, J. F. Blaize, J. Tachjadi, and A. El Idrissi, “Taurine regulates insulin release from pancreatic beta cell lines,” Journal of Biomedical Science, vol. 17, supplement 1, p. S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. H. O. Goodman and Z. K. Shihabi, “Supplemental taurine in diabetic rats: effects on plasma glucose and triglycerides,” Biochemical Medicine and Metabolic Biology, vol. 43, no. 1, pp. 1–9, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. Kelly, P. Aaltonen, A. J. Cox et al., “Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies,” Nephrology Dialysis Transplantation, vol. 17, no. 7, pp. 1327–1332, 2002. View at Google Scholar · View at Scopus
  36. J. J. Kim, J. J. lin, D. S. Jung et al., “Differential expression of nephrin according to glomerular size in early diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 18, no. 8, pp. 2303–2310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. R. G. Langham, D. J. Kelly, A. J. Cox et al., “Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition,” Diabetologia, vol. 45, no. 11, pp. 1572–1576, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. K. H. Chen, C. C. Hung, H. H. Hsu, Y. Jing, C. Yang, and J. Chen, “Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats,” Chemico-Biological Interactions, vol. 190, no. 1, pp. 45–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. C. C. Chang, C. Y. Chang, Y. T. Wu, J. Huang, T. Yen, and L. Hung, “Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase,” Journal of Biomedical Science, vol. 18, no. 1, p. 47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Carmeliet, V. Ferreira, G. Breier et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,” Nature, vol. 380, no. 6573, pp. 435–439, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. E. N. Unemori, N. Ferrara, E. A. Bauer, and E. P. Amento, “Vascular endothelial growth factor induced interstitial collagenase expression in human endothelial cells,” Journal of Cellular Physiology, vol. 153, no. 3, pp. 557–562, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Wolf, S. Chen, and F. N. Ziyadeh, “From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy,” Diabetes, vol. 54, no. 6, pp. 1626–1634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. H. K. Sun, Y. M. Lee, K. H. Han et al., “Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney,” The Korean Journal of Internal Medicine, vol. 27, no. 2, pp. 163–170, 2012. View at Publisher · View at Google Scholar
  44. V. Eremina, H. J. Baelde, and S. E. Quaggin, “Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier,” Nephron-Physiology, vol. 106, no. 2, pp. p32–p37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. C. A. Bertuccio, “Relevance of VEGF and nephrin expression in glomerular diseases,” Journal of Signal Transduction, vol. 2011, Article ID 718609, 9 pages, 2011. View at Publisher · View at Google Scholar
  46. H. Harada, T. Tsujino, Y. Watari, H. Nonaka, N. Emoto, and M. Yokoyama, “Oral taurine supplementation prevents fructose-induced hypertension in rats,” Heart and Vessels, vol. 19, no. 3, pp. 132–136, 2004. View at Publisher · View at Google Scholar · View at Scopus